-
2024-513317-12-00
5
2025-02-05
Pancreatic cancer
-
2024-513077-48-00
5
2024-12-19
O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer
-
2023-510022-33-00
5
2024-10-02
HIV-1 infection
-
2023-506602-39-00
6
2024-08-01
schizophrenia, schizoaffective disorder, schizophrenifom disorder
-
2023-505303-23-00
5
2024-07-26
Obesity
-
2023-507901-32-00
3
2024-06-28
Relapsed or Refractory Multiple Myeloma (R/R MM)
-
2023-504214-30-00
5
2024-06-27
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
-
2023-508099-12-00
5
2024-06-20
Dermatitis atopic
-
2023-503221-19-00
4
2024-04-18
Advanced Non-Small Cell Lung Cancer
-
2022-502405-15-01
4
2024-04-08
Mantle Cell Lymphoma (MCL)
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-501478-21-00
5
2024-03-15
Atopic Dermatitis
Eczema
-
2022-501890-38-00
4
2024-02-16
acute ischemic stroke
-
2024-511337-35-00
4
2023-11-16
The trial will include patients with so called "fusion-driven", metast
-
2022-502286-16-00
5
2023-10-27
Primary Generalized Tonic-Clonic Seizures
-
2023-503290-38-00
4
2023-09-05
Bronchiectasis
-
2022-501703-27-00
5
2023-07-05
Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
-
2022-500275-31-00
5
2023-06-20
Haemophilia A
-
2023-509810-13-00
4
2023-05-13
Acute Lymphoblastic Leukemia (ALL)
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic